<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01133678</url>
  </required_header>
  <id_info>
    <org_study_id>10-069-B</org_study_id>
    <nct_id>NCT01133678</nct_id>
  </id_info>
  <brief_title>Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck</brief_title>
  <official_title>Selection of Chemoradiotherapy Based on Response to Induction Chemotherapy - a Phase II Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary

      Compare response rates to induction chemotherapy consisting of cisplatin/paclitaxel/cetuximab
      +/- everolimus.

      Secondary

      Determine the maximum administered dose (MAD), maximum tolerated dose (MTD), dose limiting
      toxicity (DLT), and safety of everolimus with cisplatin/paclitaxel/cetuximab induction
      chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 4, 2010</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor Responses</measure>
    <time_frame>2 years</time_frame>
    <description>To assess the rates of the tumor</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Everolimus escalating dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Find the highest safe dose of Everolimus when combined with induction chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Everolimus or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will receive Everolimus or Placebo (dose determined in Phase 1 portion)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus escalating dose</intervention_name>
    <description>Phase I Portion (2 21-day cycles) Cisplatin (100mg/m2 day 1) Paclitaxel(175mg/m2, day 1) Cetuximab(400 mg/m2 loading dose day 1 then 250mg/m2 weekly ) Everolimus escalating dose</description>
    <arm_group_label>Everolimus escalating dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus or Placebo</intervention_name>
    <description>Phase II Portion (2 28-day cycles) Cisplatin (100mg/m2 day 1) Paclitaxel(175mg/m2, day 1) Cetuximab(400 mg/m2 loading dose day 1 then 250mg/m2 weekly ) Everolimus dose determined in phase I</description>
    <arm_group_label>Everolimus or Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment naïve stage III (hypopharynx, or nasopharynx primary) or stage IVa/IVb (all
             sites) histologically proven SCCHN with no definitive evidence of metastatic disease

          -  Patients with unknown primary site of tumor and histologically proven squamous cell
             carcinoma of a cervical lymph node felt to arise from a site in the head and neck are
             eligible

          -  Patients must have at least one measurable site of disease according to RECIST
             criteria

          -  Age ≥ 18 years

          -  Karnofsky performance status &gt; 70%

          -  Adequate bone marrow function as shown by: ANC ≥ 1.5 x 109/L, Platelets ≥ 100 x 109/L,
             Hb &gt;9 g/dL

          -  Adequate liver function as shown by:

          -  Serum bilirubin ≤ 1.5 x ULN

          -  ALT and AST ≤ 2.5x ULN

          -  INR and PTT ≤1.5. (Anticoagulation is allowed if target INR ≤ 1.5 on a stable dose of
             warfarin or on a stable dose of LMW heparin for &gt;2 weeks at time of randomization.)

          -  Adequate renal function: serum creatinine ≤ 1.5 x ULN

          -  Fasting serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L AND fasting triglycerides ≤ 2.5 x
             ULN. NOTE: In case one or both of these thresholds are exceeded, the patient can only
             be included after initiation of appropriate lipid lowering medication.

          -  Signed informed consent

        Exclusion Criteria:

          -  Patients currently receiving anticancer therapies or who have received anticancer
             therapies within 4 weeks of the start of study drug (including chemotherapy, radiation
             therapy, antibody based therapy, etc.)

          -  Patients, who have had a major surgery [defined as requiring general anesthesia but
             not including tonsillectomy, neck dissection, or panendoscopy (triple endoscopy or
             examination under general anesthesia)], or significant traumatic injury within 4 weeks
             of start of study drug; patients who have not recovered from the side effects of any
             major surgery; or patients that may require major surgery during the course of the
             study

          -  Prior treatment with any investigational drug within the preceding 4 weeks

          -  Patients receiving chronic, systemic treatment with corticosteroids or another
             immunosuppressive agent. Topical or inhaled corticosteroids are allowed.

          -  Patients should not receive immunization with attenuated live vaccines within one week
             of study entry or during study period

          -  Unequivocal demonstration of metastatic disease (i.e. M1 disease).

          -  Other malignancies within the past 3 years except for adequately treated carcinoma of
             the cervix or basal or squamous cell carcinomas of the skin.

          -  Patients who have any severe and/or uncontrolled medical conditions or other
             conditions that could affect their participation in the study such as:

          -  Symptomatic congestive heart failure of New York heart Association Class III or IV

          -  Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction
             within 6 months of start of study drug, serious uncontrolled cardiac arrhythmia or any
             other clinically significant cardiac disease

          -  Severely impaired lung function as defined as spirometry and DLCO that is 50% of the
             normal predicted value and/or 02 saturation that is 88% or less at rest on room air

          -  Uncontrolled diabetes as defined by fasting serum glucose &gt;1.5 x ULN

          -  Active (acute or chronic) or uncontrolled severe infections

          -  Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent
             hepatitis

          -  A known history of HIV seropositivity

          -  Impairment of gastrointestinal function or gastrointestinal disease that may
             significantly alter the absorption of everolimus (e.g., ulcerative disease,
             uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel
             resection)

          -  Nota bene: subjects that require administration of everolimus through a feeding tube
             are allowed to participate

          -  Patients with an active, bleeding diathesis

          -  Female patients who are pregnant or breast feeding, or adults of reproductive
             potential who are not using effective birth control methods. If barrier contraceptives
             are being used, these must be continued throughout the trial by both sexes. Hormonal
             contraceptives are not acceptable as a sole method of contraception. (Women of
             childbearing potential must have a negative urine or serum pregnancy test within 7
             days prior to administration of everolimus)

          -  Patients who have received prior treatment with an mTOR inhibitor for SCCHN
             (sirolimus, temsirolimus, everolimus).

          -  Patients with a known hypersensitivity to everolimus (everolimus) or other rapamycins
             (sirolimus, temsirolimus) or to its excipients

          -  Patients with a know hypersensitivity to cetuximab, cremaphor, paclitaxel,
             carboplatin, 5FU, hydroxyurea, or any compounds of similar chemical or biologic
             composition

          -  History of noncompliance to medical regimens

          -  Patients unwilling to or unable to comply with the protocol

          -  Baseline neurologic deficit (&gt; grade II neuropathy)

          -  Prior severe infusion reaction (grade 4) to a monoclonal antibody
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Everett Vokes, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Chicago Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthShore University Health System</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://uccrc.uchicago.edu</url>
    <description>The University of Chicago Comprehensive Cancer Center Web Page</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2010</study_first_submitted>
  <study_first_submitted_qc>May 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2010</study_first_posted>
  <last_update_submitted>October 9, 2017</last_update_submitted>
  <last_update_submitted_qc>October 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Squamous Cell Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

